PA
IMVT icon

Perceptive Advisors’s Immunovant IMVT Stock Holding History

Perceptive Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$5.28M – 115
2024
Q2 		$5.28M Buy
200,000
+100,000
+100% +$2.84M 0.13% 78
2024
Q1 		$3.23M Buy
+100,000
New +$3.65M 0.06% 100

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Perceptive Advisors's IMVT Position: Q1 2026 in Review

Perceptive Advisors reduced its Immunovant (IMVT) stake by 20% in Q1 2026, selling an estimated $10.3M and leaving 1,597,383 shares worth $39.7M. The position accounts for 0.78% of the portfolio, ranked #30.

Perceptive Advisors first reported a position in IMVT in Q2 2020 and has held it in 17 quarters since. The position peaked at $146M in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Perceptive Advisors held 1,597,383 shares of Immunovant worth $39.7M as of Q1 2026.
  • Perceptive Advisors sold 397,507 Immunovant shares in Q1 2026, an estimated $10.3M.
  • Immunovant made up 0.78% of Perceptive Advisors's portfolio in Q1 2026, its #30 holding.
  • Perceptive Advisors first reported a position in Immunovant in Q2 2020 and has held it in 17 quarters since.
  • Perceptive Advisors's Immunovant position peaked at $146M in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.